-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653.O2.6 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Initial Therapy

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, antibodies, Biological, multiple myeloma, Diseases, Non-Biological, smoldering myeloma, Combinations, Elderly, Therapies, Biological Processes, Technology and Procedures, cytogenetics, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, multi-systemic interactions
Monday, December 7, 2020: 7:00 AM-8:30 AM
Moderators:
Noa Biran, MD, John Theurer Cancer Center, Hackensack Meridian Health, Division of Multiple Myeloma and Agne Paner, MD, Rush University Medical Center
Disclosures:
Biran: Amgen: Consultancy, Honoraria, Other: reimbursement of travel and accomodation, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Other: reimbursement of travel and accomodation, Research Funding, Speakers Bureau; Sanofi: Honoraria, Speakers Bureau; Karyopharma: Research Funding; Oncopeptides: Consultancy; BMS: Consultancy, Honoraria, Other: reimbursement of travel and accommodation, Research Funding, Speakers Bureau. Paner: Kayropharm: Consultancy; Amgen: Consultancy; Celgene: Consultancy; Oncopeptides: Consultancy; GSK: Consultancy.
7:00 AM

Dickran Kazandjian, MD1, Elizabeth Hill, MD2, Candis Morrison, CNP, PhD2*, Alexander Dew, DO, MS3, Neha Korde, MD4, Sham Mailankody, MBBS4, Elisabet E. Manasanch, MD5, Mary L. Kwok, MD6, Manisha Bhutani, MD7, Nishant Tageja, MD8, Yong Zhang, Ph.D.9*, Ashley Carpenter, RN2*, Monica Epstein, RN2*, Michael Emanuel, BSN, RN10*, Crystal Lu, PharmD, BCOP11*, Raul C. Braylan, MD12, Katherine R. Calvo, MD, PhD12, Peter Choyke, MD13*, Alina Dulau-Florea, MD14*, Esther Mena, MD13*, Liza Lindenberg, MD13*, Irina Maric, MD, MSci15, Nisha Patel, DO16*, Maryalice Stetler-Stevenson, MD, PhD17*, Hao-Wei Wang, MD, PhD18, Constance M. Yuan, MD, PhD17*, Seth M. Steinberg, PhD19*, William D. Figg, PhD20*, Mark Roschewski, MD21 and Ola Landgren, MD, PhD4

1Center for Cancer Research, Lymphoid Malignancies Branch, Multiple Myeloma Program, NIH, Potomac, MD
2Center for Cancer Research, Lymphoid Malignancies Branch, Multiple Myeloma Program, National Cancer Institute, National Institutes of Health, Bethesda, MD
3Walter Reed Medical Center, North Bethesda, MD
4Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
6Walter Reed National Military Medical Ctr., Bethesda, MD
7Levine L. Cancer Institute, Charlotte, NC
8Wheeling Hospital, Monroeville, PA
9National Cancer Institute, National Institutes of Health, Center for Cancer Research, Bethesda, MD
10Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
11Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD
12Hematology Section, Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD
13Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
14National Institutes of Health Clinical Center, Bethesda, MD
15Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD
16National Institutes of Health, Bethesda, MD
17Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD
18Department of Laboratory Medicine, National Cancer Institute, National Institute of Health, Bethesda, MD
19Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD
20Molecular Pharmacology Section, Genitourinary Malignancies Section, National Cancer Institute, Bethesda, MD
21Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

7:15 AM

Jonathan L. Kaufman, MD1, Jacob P. Laubach2*, Douglas Sborov, MD, MS3, Brandi Reeves, MD4, Cesar Rodriguez, MD5, Ajai Chari6*, Rebecca W. Silbermann, MD7, Luciano J. Costa, MD, PhD8, Larry D. Anderson Jr., MD, PhD9, Nitya Nathwani, MD10, Nina Shah, MD11, Yvonne A. Efebera, MD, MPH12, Sarah A. Holstein, MD, PhD13, Caitlin Costello14*, Andrzej Jakubowiak, MD, PhD15, Tanya M. Wildes, MD, MSc16, Robert Z. Orlowski, MD, PhD17, Kenneth H. Shain, MD, PhD 18, Andrew J. Cowan19*, Yana Lutska, PharmD20*, Padma Bobba20*, Huiling Pei, PhD21*, Jon Ukropec, PhD22, Jessica Vermeulen, MD, PhD23, Thomas S. Lin, MD, PhD20, Paul G. Richardson, MD2 and Peter M. Voorhees24*

1Winship Cancer Institute, Emory University, Atlanta, GA
2Dana-Farber Cancer Institute, Boston, MA
3Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
4University of North Carolina-Chapel Hill, Chapel Hill, NC
5Wake Forest University School of Medicine, Winston-Salem, NC
6Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
7Knight Cancer Institute, Oregon Health and Science University, Portland, OR
8University of Alabama at Birmingham, Birmingham, AL
9Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
10Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA
11Department of Medicine, University of California San Francisco, San Francisco, CA
12The Ohio State University Comprehensive Cancer Center, Columbus, OH
13Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE
14Moores Cancer Center, University of California San Diego, La Jolla, CA
15University of Chicago Medical Center, Chicago, IL
16Division of Oncology, Section Medical Oncology, Washington University School of Medicine, St. Louis, MO
17Department of Lymphoma–Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX
18Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
19Division of Medical Oncology, University of Washington, Seattle, WA
20Janssen Scientific Affairs, LLC, Horsham, PA
21Janssen Research & Development, LLC, Titusville, NJ
22Janssen Global Medical Affairs, Horsham, PA
23Janssen Research & Development, LLC, Leiden, Netherlands
24Levine Cancer Institute, Atrium Health, Charlotte, NC

7:30 AM

Pieter Sonneveld, MD, PhD1, Meral Beksac, MD2, Bronno Van Der Holt, PhD3*, Meletios A Dimopoulos4, Angelo Michele Carella, MD5*, Heinz Ludwig, MD6, Sonja Zweegman, MD, PhD7, Thilo Zander, MD8*, Ruth Wester, MD1*, Roman Hajek, MD9, Lucia Pantani, MD, PhD10*, Luca Dozza, MSc10*, Francesca Gay, MD11, Anna Maria Cafro12*, Luca De Rosa13*, Francesca Fioritoni, MD14*, Ulf-Henrik Mellqvist, MD, PhD15, Rossella Troia, PharmD16*, Niels Frost Andersen, MD, PhD17*, Ka Lung Wu, MD, PhD18, Christoph Driessen, MD19, Susana Carvalho, MD20*, Alexandra J. Croockewit, MD, PhD21*, Fredrik Schjesvold, MD, PhD22, Massimo Offidani23, Michele Cavo10* and Mario Boccadoro24

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Department of Hematology, Ankara University, Ankara, Turkey
3HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
4University of Athens School of Medicine, KIFISIA, Greece
5IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
6Wilhelminenspital, Vienna, Austria
7Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
8Medical Oncology, Luzerner Kantonsspital, Luzern, Switzerland
9University Hospital Ostrava, Ostrava, Czech Republic
10Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic and Experimental Medicine, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy
11Myeloma Unit, Division of Hematology, University of Torino, A.O.U. S. Giovanni Battista, Torino, IT-TO, Italy
12Hematology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Milan, Italy
13Ospedale San Camillo Forlanini, Roma, ITA
14Department of Hematology, Transfusion Medicine and Biotechnology, "Santo Spirito" Civic Hospital, Pescara, Italy
15Department of Hematology, South Älvsborg Hospital, Boras, Sweden
16GIMEMA, European Myeloma Network, Italy
17Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
18Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
19Department of Oncology and Hematology, Laboratory of Experimental Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
20Instituto Português de Oncologia, Lisbon, Portugal
21Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands
22Oslo Myeloma Center/Department of Hematology, OSLO Univeristy Hospital, Oslo, Norway
23GIMEMA, European Myeloma Network, Ancona, Italy
24Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Torino, Italy

7:45 AM

Thierry Facon, MD1*, Christopher P. Venner2*, Nizar Bahlis, MD3, Fritz Offner, MD, PhD4, Darrell J White, MD5, Lotfi Benboubker, MD6*, Sophie Rigaudeau, MD7*, Philippe Rodon, MD8, Sung-Soo Yoon, MD, PhD9, Kenshi Suzuki, MD, PhD10, Hirohiko Shibayama, MD, PhD11, Xiaoquan Zhang, MD12*, Godwin Yung12*, Robert M. Rifkin, MD13, Philippe Moreau14*, Sagar Lonial, MD15, Shaji K. Kumar, MD16, Paul G. Richardson, MD17 and S. Vincent Rajkumar, MD18

1Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille, Lille, France
2Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
3Division of Hematology and Oncology, Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
4Hematology, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium
5QEII Health Sciences Center and Dalhousie University, Halifax, NS, Canada
6Service d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France
7Department of Clinical Hematology, Centre Hospitalier Versailles, Le Chesnay, France
8Unite d'Hematologie et d'Oncologie, Centre Hospitalier Périgueux, Périgueux, France
9Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
10Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
11Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan
12Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
13Rocky Mountain Cancer Center, Denver, CO
14Department of Hematology, University Hospital of Nantes, Nantes, France
15Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
16Division of Hematology, Mayo Clinic, Rochester, MN
17Dana-Farber Cancer Institute, Boston, MA
18Mayo Clinic Rochester, Division of Hematology, Rochester, MN

8:00 AM

Raymond L. Comenzo, MD1, Efstathios Kastritis, MD2*, Giovanni Palladini, MD, PhD3, Monique C. Minnema4, Ashutosh D. Wechalekar, MBBS, FRCP, FRCPath, DM5, Arnaud Jaccard, MD, PhD6*, Vaishali Sanchorawala, MD7, Hans C. Lee, MD8, Simon D. Gibbs, FRACP, FRCPA, MBBS9*, Peter Mollee, FRACP, MBBS, MSc, FRCPA10, Christopher P. Venner, MD11, Jin Lu12, Stefan Schönland, MD13*, Moshe Gatt, MD14, Kenshi Suzuki, MD, PhD15, Kihyun Kim, MD, PhD16, M. Teresa Cibeira, MD, PhD17*, Meral Beksac, MD18, Edward Libby, MD19, Jason Valent, MD20, Vania T. M. Hungria, MD, PhD21, Sandy W. Wong, MD22, Michael Rosenzweig, MD23, Naresh Bumma, MD24, Dominique Chauveau, MD, PhD25*, Meletios A Dimopoulos26, NamPhuong Tran, MD27*, Xiang Qin, MD, PhD28*, Sandra Y. Vasey, MSc28*, Brenda Tromp, MSc29, Brendan M. Weiss, MD28*, Jessica Vermeulen, MD, PhD30 and Giampaolo Merlini, MD31

1Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece
3Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, PV, Italy
4Department of Hematology, UMC Utrecht, Utrecht, Netherlands
5University College London, London, United Kingdom
6Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France
7Amyloidosis Center, Boston University School of Medicine, Boston, MA
8Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
9The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Easter Health Clinical School, Melbourne, VIC, Australia
10Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
11Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
12Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing, China
13Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
14Department of Hematology, Hadassah-Hebrew University Medical Center-, Jerusalem, Israel
15Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan
16Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
17Hospital Clinic of Barcelona, Barcelona, Spain
18Cebeci Yerleskesi Dikimevi, Ankara, Turkey
19Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
20Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
21São Germano Clinic, São Paulo, Brazil
22Tufts Medical Center, San Francisco, CA
23Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
24Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
25CHU de Toulouse-Hôpital Rangueil, Toulouse, France
26University of Athens School of Medicine, KIFISIA, Greece
27Janssen Research & Development, LLC, Los Angeles, CA
28Janssen Research & Development, LLC, Spring House, PA
29Janssen Research & Development, LLC, Leiden, Netherlands
30Janssen Research & Development, LLC, Leiden, CB, Netherlands
31Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy

8:15 AM

Giovanni Palladini, MD, PhD1, Stefan Schönland, MD2*, Giampaolo Merlini, MD1, Paolo Milani, MD, PhD1, Arnaud Jaccard, MD, PhD3*, Frank Bridoux, MD, PhD4*, Wilfried Roeloffzen, MD, PhD5*, M. Teresa Cibeira, MD, PhD6*, Hermine Agis, MD7, Monique C. Minnema, MD, PhD8, Rui Bergantim, MD9*, Roman Hajek, MD, PhD10, Cristina João, MD, PhD, MSc11*, Ashutosh D. Wechalekar, MBBS, FRCP, FRCPath, DM12, Pieter Sonneveld, MD, PhD13 and Efstathios Kastritis, MD14*

1Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy
2Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany
3National Amyloidosis Center and Hematology Unit, CHU Limoges, Limoges, France
4Nephrology Unit, CHU Poitiers, Poitiers, France
5Amyloidosis Centre of Expertise Department of Internal Medicine, Faculty of Medical Sciences,, University Medical Center Groningen, Groningen, Netherlands
6Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, Barcelona, Spain
7Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria
8Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
9Department of Hematology, Hospital São João, Porto, Portugal
10Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
11Hematology Department, Champalimaud Centre for the Unknown, Lisbon, Portugal
12National Amyloidosis Centre, University College London, London, United Kingdom
13Erasmus MC Cancer Institute, Rotterdam, Netherlands
14Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

*signifies non-member of ASH